NCT03261011View on ClinicalTrials.gov

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

August 27, 2021

Study Completion Date

April 13, 2023

Conditions

Advanced Cancer

Interventions

BIOLOGICAL

AK-104

Subjects will receive AK104 by intravenous administration.

Trial Locations (6)

2010

St Vincent's Hospital Sydney, Darlinghurst

3002

Peter MacCallum Cancer Centre, Melbourne

3084

Austin Health, Heidelberg

3168

Monash Health, Clayton

4101

Integrated Clinical Oncology Network (ICON), South Brisbane

6009

Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands

All Listed Sponsors

lead

Akesobio Australia Pty Ltd

INDUSTRY

NCT03261011 - Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter